Top

Journal of Gastrointestinal Surgery

Published in:

01-01-2021 | Ulcerative Colitis | SSAT Plenary Presentation

Declining Rates of Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy

Authors: Sarina C. Lowe, Jenny S. Sauk, Berkeley N. Limketkai, Mary R. Kwaan

Published in: Journal of Gastrointestinal Surgery | Issue 1/2021

Abstract

Background

Medical therapy for inflammatory bowel disease (IBD) has markedly advanced since the introduction of biologic therapeutics, although surgery remains an important therapeutic strategy for both Crohn’s disease (CD) and ulcerative colitis (UC). This study evaluated how rates of bowel resection surgery and post-operative mortality for IBD have changed over the last decade in the era of biologic therapies.

Methods

The Nationwide Readmission Database (NRD) was queried for patients with IBD (based on ICD-9 and -10 diagnosis and procedure codes) who were hospitalized between 2010 and 2017. Longitudinal trends in bowel resection surgery, urgent surgery, and post-operative mortality were analyzed.

Results

During the 8-year period, a total of 1795,266 IBD-related hospitalizations (1,072,110 with CD and 723,156 with UC) were evaluated. There was an increase in the annual number of IBD patients hospitalized, but a statistically significant decrease in the proportion of IBD patients undergoing surgery, from 10 to 8.8% (p < 0.001) for CD and 7.7 to 7.5% (p < 0.001) for UC. From 2014 through 2017, the proportion of urgent surgeries remained stable around 25% (p = 0.16) for CD and decreased from 21 to 14% (p < 0.001) for UC. For CD, the rate of post-operative 30-day mortality varied between 1.2 and 1.6% and for UC decreased from 5.8 to 2.3% (p < 0.001).

Conclusions

Analysis of a nationwide dataset from 2010 to 2017 determined that despite an increase in total admissions for IBD, a smaller proportion of hospitalized patients underwent surgery. A greater proportion of surgeries for UC were performed on an elective basis, and overall the rates of post-operative mortality for CD and UC decreased. The growth of biologic medical therapy during the study period highlights a probable contributing factor for the observed changes.

Available only for authorised users

San-Juan-Rodriguez A, Prokopovich MV, Shrank WH, Good CB, Hernandez I. Assessment of Price Changes of Existing Tumor Necrosis Factor Inhibitors After the Market Entry of Competitors. JAMA Intern Med. 2019;179(5):713–6. https://doi.org/10.1001/jamainternmed.2018.7656.CrossRefPubMedPubMedCentral

Armuzzi A, DiBonaventura MD, Tarallo M, Lucas J, Bluff D, Hoskin B et al. Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. PLoS One. 2020;15(1):e0227914. https://doi.org/10.1371/journal.pone.0227914.CrossRefPubMedPubMedCentral

Targownik LE, Tennakoon A, Leung S, Lix LM, Singh H, Bernstein CN. Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis. Clin Gastroenterol Hepatol. 2017;15(7):1061–70 e1. https://doi.org/10.1016/j.cgh.2017.01.035.CrossRefPubMed

Carter MJ, Lobo AJ, Travis SP, Ibd Section BSoG. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:V1–16. https://doi.org/10.1136/gut.2004.043372.

Andrews HA, Lewis P, Allan RN. Prognosis after surgery for colonic Crohn’s disease. Br J Surg. 1989;76(11):1184–90. https://doi.org/10.1002/bjs.1800761123.CrossRefPubMed

Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn’s Disease in Adults. Am J Gastroenterol. 2018;113(4):481–517. https://doi.org/10.1038/ajg.2018.27.CrossRefPubMed

Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76. https://doi.org/10.1056/NEJMoa050516.CrossRefPubMed

Hatch QM, Ratnaparkhi R, Althans A, Keating M, Neupane R, Nishtala M et al. Is Modern Medical Management Changing Ultimate Patient Outcomes in Inflammatory Bowel Disease? J Gastrointest Surg. 2016;20(11):1867–73. https://doi.org/10.1007/s11605-016-3275-z.CrossRefPubMed

Guasch M, Canete F, Ordas I, Iglesias-Flores E, Clos A, Gisbert JP et al. Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. J Gastroenterol Hepatol. 2020. https://doi.org/10.1111/jgh.15084.

10.

Rungoe C, Langholz E, Andersson M, Basit S, Nielsen NM, Wohlfahrt J et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut. 2014;63(10):1607–16. https://doi.org/10.1136/gutjnl-2013-305607.CrossRefPubMed

11.

Justiniano CF, Aquina CT, Becerra AZ, Xu Z, Boodry CI, Swanger AA et al. Postoperative Mortality After Nonelective Surgery for Inflammatory Bowel Disease Patients in the Era of Biologics. Ann Surg. 2019;269(4):686–91. https://doi.org/10.1097/SLA.0000000000002628.CrossRefPubMed

12.

de Silva S, Ma C, Proulx MC, Crespin M, Kaplan BS, Hubbard J et al. Postoperative complications and mortality following colectomy for ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9(11):972–80. https://doi.org/10.1016/j.cgh.2011.07.016.CrossRefPubMed

13.

Quality AoHRa. Introduction to the HCUP Nationwide Readmissions Database (NRD) 2010-20172019.

14.

Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9. https://doi.org/10.1016/0895-4356(92)90133-8.CrossRefPubMed

15.

Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Safdi M, Popp JW, Jr. et al. Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience. Inflamm Bowel Dis. 2018;24(3):490–501. https://doi.org/10.1093/ibd/izx072.CrossRefPubMedPubMedCentral

16.

Johnson J. Johnson & Johnson Quarterly Reports 2010-2016.

17.

Yu H, MacIsaac D, Wong JJ, Sellers ZM, Wren AA, Bensen R et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment Pharmacol Ther. 2018;47(3):364–70. https://doi.org/10.1111/apt.14430.CrossRefPubMed

18.

Cannom RR, Kaiser AM, Ault GT, Beart RW, Jr., Etzioni DA. Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates? Am Surg. 2009;75(10):976–80.CrossRefPubMed

19.

Bewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol. 2007;5(5):597–601. https://doi.org/10.1016/j.cgh.2007.01.015.CrossRefPubMed

20.

Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54 e42; quiz e30. https://doi.org/10.1053/j.gastro.2011.10.001.CrossRefPubMed

21.

Nguyen GC, Tuskey A, Dassopoulos T, Harris ML, Brant SR. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis. 2007;13(12):1529–35. https://doi.org/10.1002/ibd.20250.CrossRefPubMed

22.

Ahmad A, Laverty AA, Alexakis C, Cowling T, Saxena S, Majeed A et al. Changing nationwide trends in endoscopic, medical and surgical admissions for inflammatory bowel disease: 2003-2013. BMJ Open Gastroenterol. 2018;5(1):e000191. https://doi.org/10.1136/bmjgast-2017-000191.CrossRefPubMedPubMedCentral

23.

Ma C, Moran GW, Benchimol EI, Targownik LE, Heitman SJ, Hubbard JN et al. Surgical Rates for Crohn’s Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study. Am J Gastroenterol. 2017;112(12):1840–8. https://doi.org/10.1038/ajg.2017.394.CrossRefPubMedPubMedCentral

24.

Roberts SE, Williams JG, Yeates D, Goldacre MJ. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn’s disease: record linkage studies. BMJ. 2007;335(7628):1033. https://doi.org/10.1136/bmj.39345.714039.55.CrossRefPubMedPubMedCentral

25.

D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763–86. https://doi.org/10.1053/j.gastro.2006.12.038.CrossRefPubMed

26.

Abelson JS, Michelassi F, Mao J, Sedrakyan A, Yeo H. Higher Surgical Morbidity for Ulcerative Colitis Patients in the Era of Biologics. Ann Surg. 2018;268(2):311–7. https://doi.org/10.1097/SLA.0000000000002275.CrossRefPubMed

27.

Frolkis AD, Dykeman J, Negron ME, Debruyn J, Jette N, Fiest KM et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145(5):996–1006. https://doi.org/10.1053/j.gastro.2013.07.041.CrossRefPubMed

28.

Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coenegrachts JL, Coremans G. Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut. 1984;25(6):665–72.CrossRefPubMedPubMedCentral

29.

Bettenworth D, Gustavsson A, Atreja A, Lopez R, Tysk C, van Assche G et al. A Pooled Analysis of Efficacy, Safety, and Long-term Outcome of Endoscopic Balloon Dilation Therapy for Patients with Stricturing Crohn's Disease. Inflamm Bowel Dis. 2017;23(1):133–42. https://doi.org/10.1097/MIB.0000000000000988.CrossRefPubMed

30.

Clancy C, Boland T, Deasy J, McNamara D, Burke JP. A Meta-analysis of Percutaneous Drainage Versus Surgery as the Initial Treatment of Crohn’s Disease-related Intra-abdominal Abscess. J Crohns Colitis. 2016;10(2):202–8. https://doi.org/10.1093/ecco-jcc/jjv198.CrossRefPubMed

31.

Singh S, Al-Darmaki A, Frolkis AD, Seow CH, Leung Y, Novak KL et al. Postoperative Mortality Among Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis of Population-Based Studies. Gastroenterology. 2015;149(4):928–37. https://doi.org/10.1053/j.gastro.2015.06.001.CrossRefPubMed

32.

Ultee KHJ, Tjeertes EKM, Bastos Goncalves F, Rouwet EV, Hoofwijk AGM, Stolker RJ et al. The relation between household income and surgical outcome in the Dutch setting of equal access to and provision of healthcare. PLoS One. 2018;13(1):e0191464. https://doi.org/10.1371/journal.pone.0191464.CrossRefPubMedPubMedCentral

33.

Frolkis AD, Lipton DS, Fiest KM, Negron ME, Dykeman J, deBruyn J et al. Cumulative incidence of second intestinal resection in Crohn’s disease: a systematic review and meta-analysis of population-based studies. Am J Gastroenterol. 2014;109(11):1739–48. https://doi.org/10.1038/ajg.2014.297.

Title: Declining Rates of Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy
Authors: Sarina C. Lowe
Jenny S. Sauk
Berkeley N. Limketkai
Mary R. Kwaan
Publication date: 01-01-2021
Publisher: Springer US
Keywords: Ulcerative Colitis
Crohn's Disease
Chronic Inflammatory Bowel Disease
Published in: Journal of Gastrointestinal Surgery / Issue 1/2021
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-020-04832-y

At a glance: The STEP trials

Springer Medicine

Declining Rates of Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Outcomes with Preoperative Biliary Stenting After Pancreaticoduodenectomy In the Modern Era

Laparoscopic Portal Territory Hepatectomy (Extended Segment 5) by an Indocyanine Green Fluorescent Dual Staining Technique (Video)

Is Laparoscopic CME Right Hemicolectomy an Optimal Indication for NET of the Right Colon and Terminal Ileum?

Correction to: Laparoscopic Cholecystectomy for Acute Cholecystitis: Is the Surgery Still Safe beyond the 7-Day Barrier?

A Novel Valvuloplastic Esophagogastrostomy Technique for Laparoscopic Transhiatal Lower Esophagectomy and Proximal Gastrectomy for Siewert Type II Esophagogastric Junction Carcinoma—the Tri Double-Flap Hybrid Method

Perianal Crohn’s Fistula with Malignant Transformation